https://www.selleckchem.com/pr....oducts/Aurora-A-Inhi
Only about 10% of patients underwent single modality therapy. Overall, 5-year survival ranged from 44 to 91% with a median follow-up of 3-13 years. Conclusion Children with esthesioneuroblastoma usually present at an advanced stage and undergo multi-modality therapy at a higher rate than adult patients. There is a wide range of documented overall survival though this lack of precision could be due to a paucity of patients.Background Targeted therapy has transformed the outcome for patients with metastatic renal cell carcino
Like
Comment
Share
